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Kinase inhibitors suppress the growth of oncogene driven cancer but also enforce the
selection of treatment resistant cells that are thought to promote tumor relapse in patients.
Here, we report transcriptomic and functional genomics analyses of cells and tumors within
their microenvironment across different genotypes that persist during kinase inhibitor
treatment. We uncover a conserved, MAPK/IRF1-mediated inflammatory response in tumors
that undergo stemness- and senescence-associated reprogramming. In these tumor cells,
activation of the innate immunity sensor RIG-I via its agonist IVT4, triggers an interferon and
a pro-apoptotic response that synergize with concomitant kinase inhibition. In humanized
lung cancer xenografts and a syngeneic Egfr-driven lung cancer model these effects translate
into reduction of exhausted CD8+ T cells and robust tumor shrinkage. Overall, the
mechanistic understanding of MAPK/IRF1-mediated intratumoral reprogramming may ulti-
mately prolong the efficacy of targeted drugs in genetically defined cancer patients.
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For cancer patients, the advent of precision medicine aimingat oncogenic mutations in kinases like EGFR and BRAF ledto a significant improvement of the overall survival across
different tumor types1–3. However, in virtually all patients, drug
response is followed by therapy resistance and disease progres-
sion. Tumor recurrence is thought to result from cancer cells that
evade cell death and persist during the treatment, a process that
has also been observed in preclinical models of various cancer
types. In these models drug, persistent cells remain viable in a
quiescent state of limited proliferative capacity and several
mechanisms have been proposed how cells may enter this per-
sistent state4–8.
Increasing evidence indicates that therapeutic stresses drive
tumor cells into senescence, beneficial as an arrest, but potentially
detrimental due to other senescence-associated (SA) effects4,6,9,10.
This process may involve the reprogramming of tumor cells and
activation of innate immunity networks that may subsequently
rewire the interaction of tumor cells and immune cells within their
microenvironment11,12. It has been shown that compounds such as
cyclin-dependent kinase (CDK) inhibitors and epigenetic drugs
may have the capacity to evoke similar effects through the induction
of inflammation in the tumor-microenvironment11,13–17. These
effects were in part explained by the engagement of nucleic acid
receptors (NARs) and their downstream STING- or MAVS-
dependent innate immunity pathways13–15,18,19. NARs like cGAS,
MDA5, TLR3, or RIG-I (DDX58) are conserved proteins of the
cellular innate immune system aiming to recognize foreign nucleic
acids e.g. following a virus infection to induce cell death or
improved immune recognition20,21. Exploiting their role in stimu-
lating immune recognition, NAR agonists have been used suc-
cessfully to promote response to immunotherapies22,23. In addition,
stimulation of NARs like RIG-I with synthetic agonists has been
used to directly target cancer cells and has been shown to induce
tumor cell death in pre-clinical models, which offers additional
treatment options24–26.
Here, we uncover a MAPK/IRF1-mediated transcriptional
reprogramming of senescent cancer cells that survive drug
treatment. We further define the role of inflammatory signaling
in drug-tolerant cells including upregulation of NARs and the
associated immune infiltration in vivo. Finally, we show that the
RIG-I agonist IVT4 specifically exploits the reprogrammed drug-
tolerant state and limits the outgrowth of oncogene-dependent
tumor types in vitro and invivo.
Results
Targeted drugs trigger an inflammatory program in cell-cycle
arrested cells. To study the adaptive changes during targeted
inhibition of oncogenic signaling we exposed cancer cells (n= 9)
driven by diverse activated kinases (EGFR, MET, BRAF, HER2,
ALK) to targeted drugs and performed transcriptional profiling
using RNA-seq (Supplementary Fig. 1a). Despite considerable
transcriptional heterogeneity at baseline, a combined analysis
revealed strong repression of genes related to MYC signaling and
cell cycle progression (Fig. 1a, Supplementary Fig. S1b, Supple-
mentary Table 1). Remarkably, we also observed a shared
induction of Interferon (IFN) target gene sets13,14 and an adult
tissue stem-cell gene signature (ATSC)27, which has recently been
associated with therapy-induced senescence in the joint analysis
(Fig. 1a)28. BRAF-mutant and EGFR-mutant cells showed a ten-
dency towards more pronounced transcriptional effects compared
to cell lines driven by other oncogenes (Supplementary Fig. 1b).
As expected, kinase inhibitor treatment led to caspase-dependent
cell death in a subset of cells (Supplementary Fig. 1c, d) while a
large fraction of cells arrested in a G1/G0 cell-cycle state and
remained viable for a follow-up time of at least 15 days (Fig. 1b,
Supplementary Fig. 1e)4,29. Of note, in osimertinib-treated EGFR-
mutant cells, we identified induction of p27 as a potential med-
iator of cell cycle arrest (Fig. 1b, Supplementary Fig. 1f)28. Across
different cell lines and treatments, drug-tolerant cells exhibited
characteristics of therapy-induced senescence such as positive β-
galactosidase staining, a delayed secretion of Interleukin-6 (IL-6),
higher levels of BH3 family members and histone marks
H3K9me3 and H3K27me3 (Supplementary Fig. 1h-m)10,30. To
assess the time dynamics of the observed changes we performed
time-series expression profiling of three independent EGFR-
mutant cell lines and revealed a rapid induction of ATSC and
IFN-signaling and suppression of MYC- and E2F-targets (Fig. 1c,
d, Supplementary Fig. 1n). To investigate the observed changes
on a single-cell level we performed single-cell RNA-sequencing
(scRNA-seq) of osimertinib-treated PC9 and vemurafenib-treated
Colo205 cells. Clustering based on most variable genes and based
on ATSC genes however clearly separated treated and untreated
cells (Supplementary Fig. 2a, b). The scRNA-seq confirmed
downregulation of relevant senescence-repressed markers30 such
as HMGB1 and HMGB2 and induction of a subset of known
senescence-associated secretory phenotype (SASP) genes (Sup-
plementary Fig. 2c). Furthermore, pseudo-time analysis31 of
untreated PC9 cells based on genes expressed in G1/S or G2/M32
did not show a consistent pattern of expression of SA genes in
various cell cycle phases. These findings are compatible with a
model in which cells undergo a treatment-dependent repro-
gramming and are in line with previous results obtained in
similar settings (Supplementary Fig. 2d, e)28,29. To investigate
whether similar changes appear in vivo we extended our analyses
to two independent EGFR-mutant patient-derived xenografts
(PDX), which displayed a similar upregulation of inflammatory
signaling and ATSC during the response to EGFR inhibition
(Fig. 1e, Supplementary Fig. 2f).
We next asked whether the induction of an inflammatory and
SA stemness response including SASP components in drug-
tolerant cells may also have an effect on the tumor microenviron-
ment. We therefore employed a humanized PC9 xenograft model
and observed an increase of infiltrating T-cells following
osimertinib treatment (Fig. 1f, g, Supplementary Fig. 2g). Using
the Hyperion imaging system we validated higher lymphocyte
infiltration with osimertinib treatment (Supplementary Fig. 3a–c)
and also observed a shift of proliferative activity (Ki67) from tumor
cells to CD3+ cells and cytolytic activity as measured by co-
staining of CD8 and Granzyme B under treatment (Fig. 1g,
Supplementary Fig. 3a–c). Similarly, CD8 cells were significantly
less exhausted as measured by a lower rate of TIM3+ and
PD1+CD69− CD8 cells after osimertinib treatment in flow
cytometry (Fig. 1i). We subsequently validated our findings of
transcriptional adaption mechanisms by comparing public gene
expression array data of HER2-amplified breast cancer patients
undergoing neoadjuvant treatment with the monoclonal antibody
trastuzumab33. In this cohort, we identified a very similar
induction of ATSC and IFN programs when comparing responders
vs. non-responders following neoadjuvant therapy and comparable
trends in baseline to post-treatment analysis in responders and
non-responders (Supplementary Fig. 3d). In addition, we analyzed
public RNA-seq data of BRAF-mutant melanoma patients contain-
ing samples before BRAF or BRAF+MEK inhibitor treatment,
during therapy, and after resistance had developed34. In line with
our cell line and PDX data, we observed a significant induction of
IFN, ATSC, and repression of MYC and E2F signatures when
comparing pre- vs. on-treatment samples (Fig. 1j). Furthermore,
we found an enrichment of samples on treatment for a senescence-
like expression profile30 similar to the phenotype observed in
Colo205 and PC9 cells (Fig. S3e). To assess the infiltration with
tumor-associated lymphocytes we inferred the immune cell
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Fig. 1 Kinase inhibition induces senescence-associated inflammatory signaling. a Core gene set of a combined gene set enrichment analysis (GSEA) in
oncogene-driven cancer cell lines (PC9, HCC827, HCC4006, H1993, H3122, A375, Colo205) after 3 days of treatment with their respective kinase
inhibitor. b Cell count of EGFRmut PC9 cells under osimertinib (osi, 300 nM). The upper line indicates normalized cell number, shaded areas corresponding
cell cycle distribution (n= 3). Inset: Immunoblot of cell cycle regulator genes in PC9 cells after 5 days of osimertinib treatment. c, d GSEA of time-series
RNAseq in EGFRmut cells indicates temporal adaptation processes (ATSC= adult tissue stem cell gene set, NES=Normalized enrichment score). e GSEA
of the ATSC and the IFNα gene set across the two EGFRmut PDX models (osi vs. vehicle). f Schematic of the humanized mouse model (top) and exemplary
histology of low (−), medium (+), and high (++) CD8 T cell infiltration (bottom). Scale bar 100 µm, representative images of in total n= 19 tumors of
n= 10 mice. g Digital pathology-based quantification of T cell infiltration in humanized mice following 4 days of treatment with osimertinib (5 mg/kg, n= 9
tumors) or vehicle (n= 10 tumors) (error bars indicate mean ± SEM). h Hyperion imaging mass cytometry false-color image of an osimertinib treated
tumor from (f) stained for pan-cytokeratin (CK, cyan), CD8 (green), and Granzyme B (red). The overlay of CD8 and red is colored yellow. Scale bar
100 µm, representative image of n= 6 regions. i Flow cytometry analysis of infiltrating T cells in humanized PC9 xenografts after 4 days of treatment (in
total n= 6 tumors of n= 3 mice per group; error bars indicate mean ± SEM). j RNA-seq-based GSEA of public BRAFmut melanoma patient data, comparing
patients before (Pre-treatment) with patients during BRAF or BRAF+MEK inhibition (On-treatment). k Proportion of CD8 T cell infiltration inferred from
bulk RNA-seq in the melanoma patients from (j) sequenced before (Pre, n= 11) or during (On, n= 11) kinase inhibition or after resistance (Resist, n= 10)
had developed. l Cytolytic activity as the geometric mean of granzyme A and perforin RNA expression in patients from (j). Significance was calculated by t
tests in (g), (i), (k) (l) and Kolmogorov–Smirnov-based permutation test as FDR-corrected q-values in (a), (e), (j). All tests are two-sided. Boxplots display
median (center line), 25th/75th percentile (lower/upper box hinges), whiskers extend to the most extreme value within 1.5× interquartile range (IQR) of
the hinges. Source data are provided as a Source Data file.
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composition from RNA-seq using CIBERSORT35. Comparable to
the humanized mouse model we observed a significantly higher
proportion of CD8 T-cells and NK-cells in on-treatment compared
to pre-treatment samples (Fig. 1k, Supplementary Fig. 3f, g).
Accordingly, cytolytic activity as measured by an RNA-seq-based
score36 was significantly higher in on-treatment samples (Fig. 1l).
Interestingly, the higher influx of CD8 cells in matched pre-
treatment vs. on-treatment biopsies in these patients significantly
correlated with a longer time to progression (Supplementary
Fig. 3h). This further supports a model in which the treatment-
induced reprogramming of drug-tolerant cells promotes inflam-
matory signaling including an associated response of the tumor
microenvironment.
MAPK inhibition is sufficient to induce inflammatory pro-
grams in cell-cycle arrested cells. We next investigated the spe-
cific genes that may be associated with the observed drug-induced
phenotype. Across our cell line panel, we observed a broad
consensus in the upregulation of genes involved in IFN signaling,
nucleic acid-sensing, and antigen presentation (Fig. 2a). Similar
inductions of target genes could also be validated in the mela-
noma patients and in a previously published dataset of RET-
rearranged LC-2/AD cells during RET inhibition37 (Figs. 2b
and S4a). Moreover, cells derived from a KRAS-driven pancreatic
ductal adenocarcinoma (PDAC) genetically engineered mouse
model (GEMM)38 revealed an inflammatory reprogramming
upon trametinib treatment (Fig. 2c, Supplementary Fig. 4b).
Surprisingly, despite the rapid upregulation of IFN-target genes,
no relevant secretion of IFN was detectable in the supernatant of
EGFR-mutant cells treated with osimertinib (Supplementary
Fig. 4c, d). Also, a knock-out of the IFN receptor (IFNAR1) did
not affect the osimertinib-induced activation of IFIT1 or IRF1,
while it largely abrogated the response to IFNα in PC9 cells
(Supplementary Fig. 4e). Interestingly, IFNα did not induce IRF1
expression further supporting the notion that kinase inhibitor
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RAS/MEK signaling suppresses IFN-induced transcription via
downregulation of IRF1 and we speculated that targeted inhibi-
tion of oncogenic signaling could reverse this phenotype39.
Indeed, targeted MAPK inhibition with trametinib largely reca-
pitulated the rapid kinase inhibitor-mediated induction of IRF1
and IFIT1 (Fig. 2d, Supplementary Fig. 4f–h). In contrast, these
effects were not detectable (A375, H3122) or less pronounced
(PC9, HCC4006, Colo205) when using the PI3K inhibitor api-
tolisib (Supplementary Fig. 4g,h). Similarly, MEK inhibition in
KRAS-mutant lung cancer A549 cells and BRAF inhibition in
BRAF-mutant melanoma A375 cells also increased IRF1 and
IFIT1 protein levels (Fig. 2d, right). A similar trend was evident in
KRASG12C-mutant (NRAS-KO) Lewis lung carcinoma cell lines40
when treated with a KRAS-G12C inhibitor AMG510 or trame-
tinib (Fig. S4i). Accordingly, inhibition downstream of MEK
using the ERK-inhibitor SCH779284 induced IRF1 and IFIT1
expression in PC9 cells (Supplementary Fig. 4j). Among the genes
induced by kinase inhibitor treatment were also several members
of the antigen-presenting machinery, which may diminish the
ability of tumor cells to evade the immune system (Fig. 2a).
However, we also noticed upregulation of several proteins pre-
viously linked with resistance to immune checkpoint blockade
(ICB) such as VTCN1 (B7-H4) across human cell lines and
murine PDAC cells (Supplementary Fig. 4k,l)41,42. Indeed, we
validated the increased surface expression of HLA, B2M, and
VTCN1 on EGFRmut cells which was in accordance with corre-
sponding RNA levels after osimertinib and similar responses after
trametinib treatment (Fig. 2e, Supplementary Fig. 4m). In con-
trast, PD-L1 was decreased with treatment in vitro and in vivo
(Supplementary Fig. 4n,o). Also, more generally, the gene sets
modulated upon trametinib treatment in EGFR-mutant cells
largely resembled the reprogramming induced by EGFR inhibi-
tion with a strong increase if IFN target genes (Fig. 2f). An
increase of VTCN1 protein expression was moreover evident in
several additional cell lines (n= 5 of 6) when treated with their
respective kinase inhibitors (Supplementary Fig. 4p). This indi-
cates that inhibition of the driving oncogene or of MAPK sig-
naling can alter tumor-innate inflammatory pathways that may
impact tumor-immune interactions at various levels.
Considering the drug-induced antagonistic association between
gene sets related to IFN signaling and stemness on the one hand
and cell cycle arrest markers on the other (E2F, MYC, G2M
CHK) (Figs. 1a, i and S3d) we speculated that this may reflect a
general inverse association that may be also present in untreated
primary patient samples. Indeed, correlation of single-sample
gene set enrichment analysis (ssGSEA) results in lung adeno-
carcinoma tumor (LUAD) samples and treatment-naïve BRAF-
mutant melanoma patients revealed that patients with a strong
enrichment of cell cycle-related gene sets had lower enrichment
of inflammatory and stemness signature and vice versa (Fig. 2g).
Furthermore, we observed a negative correlation of DUSP6 and
SPRY4, two negative feedback regulators of MAPK signaling43,44
with the presence of CD8+ T-cells in pre-, but not in on-
treatment BRAF-mutant melanoma patients (Fig. 2h, left,
Supplementary Fig. 4q–s). Negative correlations with CD8+
T-cells were also observed when extending the analysis to a gene
panel of a recently proposed MAPK pathway activation score
containing genes upregulated with MAPK activity45. These results
showed also that high MAPK activation was associated with
decreased presence of CD8+ T-cells (Fig. 2h, right). We obtained
similar results when we analyzed RNA-seq data of untreated
LUAD patients (Fig. 2i, Supplementary Fig. 4t). Thus, in
oncogene-dependent tumors, MAPK activity may promote an
immune evasive, proliferative state that can be reversed through
targeted inhibition of oncogene signaling.
Drug-induced IRF1 expression promotes activation of intra-
tumoral immune signaling. In the next step, we aimed to dissect
the role of MAPK signaling for the induction of IFN target genes and
potential cross-talk with cell death programs. In osimertinib-treated
EGFR-mutant cells we did not observe a difference in expression of
key IFN target genes with and without caspase inhibition (Fig. 3a,
Supplementary Fig. 5a). Since caspase-inhibition prevents
osimertinib-induced cell death (Supplementary Fig. 1d) this indicates
that cell death is dispensable in the process. Similarly, treatment with
the chemotherapeutic taxol (paclitaxel) reduced cell viability
(GI50= 16 nM), but did not induce IRF1 or IFIT1 in PC9 cells
(Fig. 3b, Supplementary Fig. 5b). This data indicates that inhibition of
the MAPK pathway and not cell death leads to inflammatory
reprogramming. To further characterize these effects we genome-
edited PC9 cells using CRISPR/Cas9 to generate osimertinib-resistant
PC9T790M+C797S cells (Fig. 3c, Supplementary Fig. 5c, d)46. As
expected, robust induction of IFN and stemness genes in RNA-Seq of
Fig. 2 MAPK-pathway mediates inflammatory signaling and immune escape. a Fold-changes by RNAseq expression analysis following 3 days kinase
inhibitor treatment in oncogene-driven cancer cell lines. b Fold-changes in BRAFmut melanoma patients sequenced before (Pre) or during (On) kinase
inhibition or after resistance (Resist) to BRAF or BRAF+MEK inhibition. c Fold-changes in primary cells derived from a KRASmut PDAC GEMM after 48 h
treatment with trametinib compared to controls. d Left: Immunoblot of key inflammatory signaling nodes in EGFRmut PC9 cells treated for 12 or 24 h with
osimertinib (osi, 300 nM) or trametinib (tram, 100 nM). Right: Immunoblot of treated KRASmut A549 (trametinib, 100 nM) and BRAFmut A375
(vemurafenib, 1 µM) for 3 days. Each representative blot of n= 3 independent experiments. e FACS estimation of surface expression in EGFRmut cells
following 3 days treatment with osimertinib (300 nM) or trametinib (100 nM). mean fluorescent intensity (MFI) as fold-change normalized to DMSO
controls. Bars display mean ± SEM of independent biological replicates (PC9 B2M/HLA: osi n= 10, tram n= 5; VTCN1: osi n= 5, tram n= 8; HCC827
B2M/HLA: osi/tram n= 4, VTCN1 osi n= 3, tram n= 4; HCC4006 HLA/B2M osi n= 6, tram n= 3, VTCN1 osi/tram n= 3); P-values adjusted by
Benjamini–Hochberg. f Combined GSEA of RNA-seq from PC9, HCC827 and HCC4006 cells treated with trametinib (100 nM, 72 h). (Significance as FDR-
corrected q-values). g Pairwise correlations of single-sample (ss) GSEA scores for key gene sets in RNA-seq of untreated BRAFmut melanoma patients
(n= 14, top) or TCGA lung adenocarcinoma patients (LUAD, n= 515, bottom). Color indicates Pearson correlation coefficients. h Left: Correlation of RNA-
seq inferred CD8 T cell infiltration with an expression of the negative MAPK feedback regulator DUSP6 in untreated BRAFmut melanoma patients (n= 11)
(TPM= transcripts per million). Right: Distribution of individual correlations of CD8 T cell proportion with an extended set of MAPK activity genes45 in
patients from (b and Fig. 1k). Distribution of the n= 10 genes’ correlation coefficients with CD8 T cell proportion was tested for significance using one-
sample t tests adjusted with Bonferroni–Holm. i Left: Correlation of RNA-seq-based CD8 T cell infiltration with DUSP6 in untreated TCGA lung
adenocarcinoma patients (n= 350) grouped as n= 10 patients per bin and normalized expression/CD8 T cell proportion as median per bin. Right:
Correlation of CD8 T cell proportion with genes of the extended n= 10 MAPK genes in unbinned patients (n= 350). Significance was calculated with two-
sided paired t tests for log fold-changes (e) and one-sample t tests in (h, right) and (i, right). Spearman correlation was used in (h, i). Boxplots display
median (center line), 25th/75th percentile (lower/upper box hinges), whiskers extend to the most extreme value within 1.5× interquartile range (IQR) of
the hinges. Data points beyond the whiskers are displayed individually. Source data are provided as a Source Data file.
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PC9T790M+C797S cells was no longer achievable by osimertinib but
with the MEK inhibitor trametinib (Fig. 3d, Supplementary Fig. 5e).
To specifically prevent MAPK inhibition during osimertinib
treatment, we generated PC9 cells that stably overexpress
BRAFV600E. Here, osimertinib treatment did not lead to induction
of IRF1, VTCN1, and of the nucleic-acid sensor RIG-I (DDX58)
(Fig. 3e, f). The re-analysis of a published gene expression dataset
of non-malignant human bronchial epithelial cells (HBEC)
further supports a model in which MAPK signaling controls
inflammation, as the induction of KRAS G12D expression led to a
suppression of the IFNα gene set (Supplementary Fig. 5f)47. We
next performed CRISPR/Cas9-based IRF1-knockouts in PC9
a b c
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cells, which suppressed trametinib-induced or osimertinib-
induced upregulation of not only IRF1 but also of IFIT1 (Fig. 3g).
Of note, the rapid and strong de-repression of IRF1 (PC9,
HCC827, HCC4006 cells) was partially accompanied by other IRF
family members, which may potentially also contribute to the
total IFN target gene output (Fig. 2a, Supplementary Fig. 5g).
Nevertheless, IRF1 knock-out significantly reduced transcrip-
tional induction of several IFN target genes compared to e.v.
control cells when treated with osimertinib, but not other IRFs
(Fig. 3h, Supplementary Fig. 5h). In a complementary approach,
transient overexpression of IRF1-induced IFN target genes in
several cell lines indicating that IRF1 alone may suffice in specific
contexts (Fig. 3i, j). Furthermore, using ChIP analyses we
identified significant recruitment of RNA polymerase II (Pol II)
and Pol II p-Ser2/Ser5 to the transcription start site (TSS), the
gene body (GB) and at the transcription termination of IRF1 and
VTCN1 upon 72 h osimertinib treatment (Fig. 3k, l). This Pol II
pattern is indicative of active transcription in contrast to the
osimertinib-induced repression of transcription of the negative
MAPK-feedback regulator DUSP6 (Supplementary Fig. 5i). Taken
together, in oncogene-driven cells inhibition of MAPK pathway
may be able to de-repress IRF1 transcription that mediates
activation of downstream inflammatory programs.
Activation of RIG-I triggers MAVS-dependent response in
tumor cells. Innate immunity sensors like RIG-I or cGAS are key
mediators of innate immune signaling20 that have recently been
shown to induce cell death when activated in cancer
cells15,16,24,48. To test the effects of direct activation of individual
NARs we employed various agonists across kinase-driven cell
lines. We found that only activation of RIG-I via IVT4 but not of
cGAS by pDNA, TLR7/8 by R848, TLR3 by untransfected poly-
(I:C), or MDA5 using TransIT-LT1 transfected poly-(I:C)
induced IL-6 (IVT4 p= 0.04), CXCL-10 (IVT4 p= 0.02) or IFN
(p= 9 × 10−5) secretion across the cells (Fig. 4a, Supplementary
Fig. 6a,b). While TLR expression was generally low in the cell
lines, response to MDA5 and cGAS agonists was limited despite
measurable RNA levels (Supplementary Fig. 6c), as described in
other tumor models22. As expected, RIG-I-mediated secretion of
cytokines was dependent on MAVS and not STING expression as
confirmed by a CRISPR/Cas9-based knockout of either MAVS or
STING (PC9 e.v. vs. sgMAVS IL-6 p= 4 × 10−5, CXCL10
p= 2 × 10−12) (Fig. 4b, Supplementary Fig. 6d–f). In contrast, the
induction of IFN target genes triggered by osimertinib (Fig. 2a)
was comparable between e.v., MAVS- and STING-knockout cells,
further underlining that MAPK- rather than MAVS-/STING-
TBK1-IRF3 signaling may be driving this response (Fig. 4c,
Supplementary Fig. S6). In line with this, in EGFR-mutant cells,
we observed a MAVS-dependent induction of TBK1 phosphor-
ylation only in cells treated with a RIG-I agonist but not in cells
treated with osimertinib (Supplementary Fig. S6). At the same
time, both IVT4 and inhibition of EGFR/MAPK signaling had a
similar effect on the induction of IRF1 but only direct RIG-I
activation led to robust PARP cleavage either alone or in com-
bination with osimertinib in PC9 cells after 24 h (Fig. 4d). Using
3′ RNA-seq we observed a massive upregulation of IFNγ target
genes, but also the upregulation of apoptosis-related genes in
two IVT4 treated cell lines (Fig. 4e). More specifically, it strongly
induced pro-apoptotic genes PUMA (BBC3) and NOXA
(PMAIP1I), which could support IVT4-mediated cell killing
(Fig. 4f). Finally, we tested the cell viability effects of direct
activation of various innate immunity sensors on a panel of cell
lines driven by diverse activated kinases. The ability to reduce
cellular viability through activation of innate immune signaling
followed the trend for the efficacy to induce cytokine secretion
that was strongest with RIG-I activation (IVT4 p= 0.006)
(Fig. 4g). Again, this effect was dependent on MAVS-expression
as determined in PC9 genome-engineered cells (Supplementary
Fig. 6i) and lasted for up to 72 h across cell lines (Supplementary
Fig. 6j). Thus, in contrast to inhibition of oncogene signaling,
direct RIG-I activation leads to a MAVS-dependent induction of
cytokine secretion and cell killing across cancer cells.
Combination of kinase inhibition and RIG-I activation is
synergistic in tumors. We next aimed to investigate the potential of
therapeutically exploiting the kinase inhibitor induced inflammatory
signaling in combination with direct RIG-I activation. Detection of
cell death induction with AnnV/PI staining revealed a synergistic
effect of osimertinib and IVT4 in EGFR-mutant PC9 cells only when
cells expressed MAVS (Fig. 5a), which tracked well with differences
in inflammatory target gene induction (Supplementary Fig. 7a).
Furthermore, in Colo205 (BRAFmut), A375 (BRAFmut), and A549
(KRASmut) we observed a significant reduction of cell viability upon
IVT4 treatment in cells pre-treated with trametinib or vemurafenib
when compared to the respective controls (Fig. 5b). Similarly, the
percentage of cell death measured by AnnV/PI-analysis was
Fig. 3 Inflammatory transcription is driven by the MAPK–IRF1 axis. a RT-qPCR analysis of IFN-target genes of PC9 cells treated with osi (300 nM),
Caspase inhibitor (Caspi; Q-VD-OPH, 10 µM) or a combination of both for 72 h. Fold-change compared to DMSO controls (mean ± SEM of n= 4
independent biological replicates). b Immunoblot of PC9 cells treated with osi (300 nM) or taxol (30 nM) for 48 h. Representative image of n= 3
independent experiments. c Viability of treated parental PC9 and CRISPR-edited PC9T790M+C797S (72 h, mean ± SEM of n= 3 independent biological
replicates). d RNA-seq-based expression changes in relevant gene sets in treated vs. control PC9T790M+C797S (72 h with n= 2 replicates across n= 2
conditions). Boxplots display median (center line), 25th/75th percentile (lower/upper box hinges), whiskers extend to the most extreme value within 1.5×
interquartile range (IQR) of the hinges. Data points beyond the whiskers are displayed individually. e, f Immunoblots of PC9-e.v. control or PC9-BRAFV600E
cells following 48 h treatment with osimertinib or trametinib. Representative images of n= 3 independent experiments each. g Immunoblot of PC9 carrying
lentiCRISPRv2 empty vector (e.v.) or an IRF1-KO (sgIRF1). h RT-qPCR analysis in osimertinib treated (300 nM, 72 h) cells from (g). Fold-changes were
calculated as 2^ddCt compared to DMSO control and normalized to GAPDH. Mean ± SEM of independent biological replicates (n= 4 MX1, IFIT1, IFI44L,
n= 5 other genes). i Immunoblot after transfection with IRF1 overexpression (oe) or empty vector (e.v.) plasmid for 72 h. Representative image of n= 4
independent experiments. j RT-qPCR analyses after 72 h IRF1 overexpression in PC9 and A375 (n= 5 and n= 4 independent transfection experiments,
respectively). Fold-changes are calculated as 2^ddCt compared to e.v. control and normalized to GAPDH, Benjamini–Hochberg corrected p-values shown,
*p= 0.02; Bars indicate mean ± SEM. k, l ChIP-qPCR analysis of total Pol II or phosphorylated Pol II pSer2/5 RNA Pol II binding to the transcription start
site (TSS), gene body (GB) and transcription termination site (Term.) of IRF1 and VTCN compared to input control after 72 h osimertinib (300 nM) or
DMSO treatment (n= 4 independent biological replicates, mean ± SEM). Significance of global treatment differences calculated on log-fold changes using
Tukey-post hoc test after two-way ANOVA adjusting for gene-specific effects in (a). Significance calculated by two-sided t tests on log-fold changes with
Benjamini–Hochberg adjustment for multiple testing in (d, j) and by two-sided t tests in (h, k, l). Source data are provided as a Source Data file.
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significantly greater following pre-treatment (Fig. 5c). Similarly,
relative viability after IVT4 treatment was observed after pre-
treatment with trametinib, but not osimertinib in PC9T790M+C797S
cells (Supplementary Fig. 7b). Finally, we asked whether forced IRF1
expression alone may suffice to induce a response to IVT4 and
indeed observed a moderate, but significant effect in PC9 cells
(Fig. 5d). Interestingly, IRF1 knock-out cells did not show relevant
differences in cell death compared to e.v. cells in response to IVT4
(Supplementary Fig. 7c). This prompted us to further investigate the
mode of cell death following IVT4 treatment. Using inhibitors of
ferroptosis (Fer1), necroptosis (Nec1s), and caspases (ZVAD) indi-
cated that IVT4 primarily induces caspase-dependent cell death
across different cell lines (Fig. S7d). It has been described previously
that kinase-inhibitor treatment increases susceptibility to apoptosis
and higher dependence on anti-apoptotic family members like
MCL129. Considering that pro-apoptotic genes NOXA and PUMA
are induced by IVT4 (Fig. 4g) we speculated that those may con-
tribute to the observed synergistic effects of osimertinib with IVT4.
Indeed, knockdown of NOXA, but not PUMA significantly reduced
the number of apoptotic cells induced by combination treatment
(Supplementary Fig. 7e, f).
To test whether we may also exploit the increased sensitivity
towards RIG-I agonists after MAPK-dependent reprogramming
in vivo we used A549 xenografts and combined trametinib
induction treatment with IVT4. In these xenografts we observed
considerable tumor shrinkage with trametinib (Supplementary
Fig. 8a). However, after the pre-treatment phase tumor shrinkage
was larger with IVT4 than with the unspecific control IVT-GAC
in trametinib treated (p= 0.01), but not in control mice
(p= 0.14) compared to the start of IVT4/IVT-GAC treatment
(Supplementary Fig. 8b). Treatment did not lead to loss of body
weight in mice (Supplementary Fig. 8c). Encouraged by these
results we next extended the analyses to our humanized PC9
xenografts that offer the presence of immune cells. In this setting,
treatment duration is more limited due to the risk of graft-versus-
host disease. Osimertinib or vehicle treatment was therefore given
in a run-in fashion and then stopped to assess IVT4 effects during
tumor regrowth. As expected, osimertinib immediately reduced
tumor growth compared to vehicle control (Fig. 5e). However,
after stopping osimertinib injection of IVT4 not only inhibited
outgrowth of the tumor compared to the non-specific control
IVT-GAC but led to a further reduction in tumor volume and a
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Fig. 4 Nucleic acid receptor agonists induces cytokine secretion and impairs cell growth in oncogene-driven cancer cells. a ELISA of IL6 secretion from
oncogene-driven cells following stimulation with NAR agonists for 16 h. (points indicate mean of n= 3 independent replicates per cell line) Boxplots display
median (center line), 25th/75th percentile (lower/upper box hinges), whiskers extend to the most extreme value within 1.5× interquartile range (IQR) of
the hinges. b Secretion of IL6 and CXCL10 in PC9 cells carrying CRISPRv2 e.v. or with a MAVS or STING sgRNA after 16 h stimulation with RIG-I agonist
IVT4 (1 ng/µL) (mean ± SEM of n= 3 independent biological replicates). c RNA-seq based expression of IFN target genes in cells from (b) treated with
osimertinib (300 nM, 3d) compared to DMSO controls. d Immunoblot following osimertinib or IVT4 treatment (1 ng/µL) (cPARP= cleaved PARP).
Representative image of n= 3 biological replicates. e GSEA analysis of joint differential expression analysis for RNA-seq of PC9 and A549 cells after 8 h
IVT4 treatment (1 ng/µL) compared to control (NES= normalized enrichment score, FDR-adjusted q-values of Kolmogorov–Smirnov-based permutation
test shown). f Expression of apoptosis-related genes in IVT4-treated cells from e (CPM= count per million). g Relative viability of cancer cell lines
stimulated with innate immunity agonists for 16 h measured with MTT assay (normalized to controls) (points indicate mean of n= 3 independent biological
replicates per cell line and agonist). Boxplots display median (center line), 25th/75th percentile (lower/upper box hinges), whiskers extend to the most
extreme value within 1.5× interquartile range (IQR) of the hinges. Significance was calculated by one-sample t tests (a, g) and two-sample t tests (b). All
tests are two-sided. Source data are provided as a Source Data file.
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lower rate of TIM3+/PD-1+CD69− CD8 cells with osi pre-
treatment (Fig. 5f, g, Supplementary Fig. 8d, e). Without
osimertinib pre-treatment, no major changes in tumor volume
were observed between IVT4 and the IVT-GAC arms (Fig. 5e, g).
Similarly, tumor outgrowth was comparable between IVT4 and
IVT-GAC in a non-humanized PC9 xenograft irrespective of
osimertinib pre-treatment, indicating a relevant induction of an
immune response by the combination treatment in the
humanized setting (Supplementary Fig. 8f).
In contrast, pre-treatment with osimertinib did not have a
major effect on the group of mice treated with a PD-L1 inhibitor
(Supplementary Fig. 8g, h). Investigating the transcriptional
profiles in the IVT4/IVT-GAC cohorts revealed induction of
IFN-target genes in IVT4-treated tumors with or without
osimertinib pre-treatment compared to the respective IVT-GAC
controls (Fig. 5h, Supplementary Fig. 8i). However, among
tumors pre-treated with osimertinib, osi/IVT-GAC (n= 6)
tumors showed a stronger enrichment of EMT and ATSC gene
sets compared to osi/IVT4-treated tumors (n= 6) (Figs. 1a
and 5h). This differential enrichment of the ATSC/EMT gene
expression profiles in osi/IVT4 vs. osi/IVT-GAC treatment may
be associated with the selection pressure of IVT4 treatment
in vivo. Accordingly, IFN target genes with increased VTCN1
levels were lower overall in osimertinib/IVT-GAC-treated tumors
(Supplementary Fig. 8j). Overall, these results show that the
combination of oncogene inhibition may induce a MAPK-
dependent transcriptional reprogramming that sensitizes lung
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Full anti-tumor activity of combinatorial IVT4 and kinase
inhibition requires CD8 and NK cells. We next aimed to
validate our data in a fully immunocompetent mouse model to
assess the tumor intrinsic and immune-mediated effects fol-
lowing kinase inhibition and upon IVT4 treatment. To this
end, we employed an Egfr-mutant, syngeneic mouse model,
which allows longer-term observation and thus a combination
of IVT4 during continuous osimertinib treatment49,50. In line
with our cellular data, osimertinib monotherapy led to
reduced tumor growth and increased expression of inflam-
matory genes also in this mouse model (Fig. 6a, b, Supple-
mentary Fig. 9a). Furthermore, following an osimertinib lead-
in, the combination of osimertinib with IVT4 induced sig-
nificant tumor shrinkage when compared to osimertinib
combined with the unspecific control IVT-GAC (Fig. 6c, d).
The combination treatment was well tolerated and not asso-
ciated with altered splenic CD4/CD8 ratio or bodyweight loss
in these mice (Supplementary Fig. 9b, c). To assess the IVT4-
induced changes in the microenvironment we analyzed
tumors in mice treated with osimertinib and IVT4 or IVT-
GAC by flow-cytometry. While the number of NK and CD8
cells were comparable between both groups, IVT4 treatment
significantly reduced PD-1 expression in tumor-infiltrating
CD8 cells (Supplementary Fig. 9d).
Prior studies have shown that anti-tumor efficacy of RIG-I
agonists is enhanced by NK or T cell-mediated effects24,51.
Since we observed direct effects of IVT4 on tumor cells
in vitro including cytokine secretion and cell death induction,
we next aimed to assess the contribution of tumor-cell
intrinsic and tumor micro-environment-related effects. Fol-
lowing the encouraging first treatment cohorts, we thus
repeated the study in our syngeneic mouse model but also
included CD8-depleted or NK-cell-depleted treatment arms
(Supplementary Fig. 9e, f). Interestingly, early after starting
IVT4 treatment tumor size reductions in all osimertinib-IVT4
arms were comparable (Fig. 6e). However, during prolonged
treatment tumor shrinkage was significantly greater in the
non-depleted osimertinib-IVT4-IgG arm compared to the
arms with CD8-cell or NK-cell depletion (Fig. 6e, f,
Supplementary Fig. 9e). In the vehicle-treated arms, no
differences in tumor volume were evident with depletion of
CD8 or NK-cells (Supplementary Fig. 9e). This suggests that
the effects of both immune cell populations may contribute to
the delayed effects of IVT4 in an in vivo setting and may
further enhance the direct tumor-cell intrinsic effects (Fig. 6g).
Discussion
Over the past decade, the therapeutic options for patients with
oncogene-driven tumors have expanded considerably and per-
sonalized therapies significantly prolong patient survival in
genetically defined subgroups1–3. Nevertheless, virtually all
responders develop resistance after a phase of response in which
tumor cells remain viable despite continuous drug exposure. This
clinical observation is in line with the notion that drug resistance
rapidly emerges even in simple cell culture monolayer models of
various cancer types4,6,7,9,10. In these models drug, persistent cells
remain viable in a quiescent state of limited proliferative
capacity4,6–8,11,12. This phenotype in part resembles the cell-cycle
arrest program observed in senescent cells during therapeutic
stress12,28. However, the stress-responsive reprogramming of
persistent cells, especially within the context of the tumor
microenvironment lacks a mechanistic framework.
To address this issue, we explored the global effects of targeted
inhibition of oncogenic signaling across time and different tumor
types. Here, we uncover an unexpected mechanistic link between
MAPK signaling and the control of inflammatory networks
during therapy-induced reprogramming of tumors. Across a
broad panel of oncogene-driven pre-clinical models, we observed
a highly conserved transcriptomic signature following kinase
inhibition including induction of IFN-target genes, which was
most pronounced in EGFR-driven and BRAF-driven cancers. We
also observed comparable patterns for BRAF-mutant melanoma
and HER2-positive breast cancer patients. Of note, the immu-
nological effects mediated by the monoclonal antibody trastuzu-
mab, which was used as a targeted therapy in the breast cancer
cohort, may also add to the observed effects. Taken together,
MAPK signaling may be actively involved in the fine-tuning of
the tumor immune-environment across cancer types.
Similar transcriptional profiles have been described following
treatment of tumor cells with epigenetic drugs15,16 or CDK-
inhibitors11,13,14,17. Of importance, our data suggest that similar
effects are inducible via inhibition of the oncogenic driver and its
downstream MAPK signaling independently of cytotoxic effects.
Limited induction of IRF1 or IFIT1 was also observed following
PI3K-inhibition in some cell lines, potentially due to cross-
pathway regulation or cell-intrinsic differences. However, across
various genotypes, this reaction appears to be driven by the
MAPK-mediated de-repression of IRF1 and subsequent upregu-
lation of IFN-response genes as indicated by RNA and ChIP data.
Surprisingly, knock-out of the IFN receptor IFNAR1 did not
impede induction of IFIT1 or IRF1 by osimertinib treatment.
Fig. 5 Targeted kinase-inhibition enhances NAR agonist-induced cell death. a Flow-cytometric analysis of cell death induction following 24 h treatment
of PC9 cells carrying CRISPRv2 e.v. or sgMAVS with DMSO/osimertinib (300 nM) and IVT4/IVT-GAC (1 ng/µL) (vertical axis displays the normalized
percentage of AnnexinV and/or PI-positive cells=% non-viable cells) (mean ± SEM of independent experiments with n= 3 osi+ IVT4, n= 4 other
treatments). b CTG assay for cell lines pre-treated (48 h) with trametinib (tram, 100 nM) or vemurafenib (vem, 1 µM) and subsequent addition of IVT4/
IVT-GAC (1 ng/µL) for 24 h. Viability was normalized to respective IVT-GAC controls (mean ± SEM log10 viability of independent experiments: n= 3
A549, vem A375, Colo205, and n= 4 otherwise). c Flow-cytometric analysis of cell death induction for cell lines pre-treated (48 h) with trametinib
(100 nM) or vemurafenib (1 µM) and subsequent addition of IVT4/IVT-GAC (1 ng/µL for 24 h (vertical axis displays the normalized percentage of
AnnexinV and/or PI-positive cells=% cell death) (mean ± SEM of independent biological replicates for A375 n= 4, A549 n= 5, Colo205 n= 3). d Flow-
cytometric analysis of cell death induction in PC9 cells transfected for 48 h with IRF1 or e.v. followed by the addition of IVT4/IVT-GAC (1 ng/µL) for 24 h
(vertical axis displays the percentage of AnnexinV and/or PI-positive cells= Cell death %) (mean ± SEM of n= 3 independent experiments). e Humanized
PC9 xenografts treated with osimertinib or vehicle p.o. followed by IVT4 or control IVT-GAC i.t. as shown in the schematic (left, n= 5 mice per arm
inoculated with 2 tumors per mouse). Relative tumor volumes are shown on the right (mean ± SEM of tumors treated with osi-IVT4 (n= 9), osi-IVT-GAC
(n= 8), veh-IVT4 (n= 6), veh-IVT-GAC (n= 6)). f Flow-cytometry of tumor-infiltrating CD4 and CD8 lymphocytes for TIM3 and PD1 expression after
4 days osimertinib and 6 days IVT4/IVT-GAC. (each data point= one of n= 4 tumors per group, error bars represent mean ± SEM). g Tumor volumes at
study end compared to treatment start in mice from (e) (each bar= one tumor). h GSEA on RNA-seq of xenograft tumors in humanized mice after pre-
treatment with osimertinib and IVT4/IVT-GAC. (FDR-adj. q-values). Significance was calculated by t tests (a, e) and paired t tests (b) adjusted for multiple
testing with Bonferroni–Holm method; ANOVA with Tukey post-hoc tests (c, f), two-way ANOVA adjusting for the mouse in osi or vehicle groups (f) and
two-way ANOVA with Tukey post hoc tests (d, g). All tests are two-sided. Source data are provided as a Source Data file.
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Fig. 6 Combined kinase inhibitor and RIG-I agonist treatment in an EGFRmut syngeneic mouse model. a RNA-seq followed by GSEA of Egfrmut syngenic
mouse models comparing all control mice (0 days, 10 days vehicle; n= 4) vs. all osi treated mice (4 days, 10 days; n= 4). Two mice per treatment time-
point, one tumor per mouse analyzed (in total n= 8 mice). b RNA-seq analysis of inflammatory gene s for mice from (a) comparing all control (0 days,
10 days vehicle) vs. all osi-treated mice (bar height indicates fold-change from differential expression analysis, error bar: standard error of the fold-change;
FDR-adjusted q-values shown). c Relative tumor volumes of syngenic Egfrmut mice treated with osimertinib or vehicle p.o. subsequent addition of IVT4 or
IVT-GAC i.t. (mean ± SEM of n= 6 tumors per group). d Change of individual tumor volumes in mice from (c). e Relative tumor volumes of syngeneic
Egfrmut mice treated with osimertinib and IVT4/IVT-GAC with the addition of depleting antibodies for CD8 or NK cells or IgG control. Volumes were
normalized to the average of the control group per time point (mean ± SEM of n= 6 tumors per group). f Individual tumor volumes from (f) at tumor
harvest displayed as percent of their volume at the start of IVT4/IVT-GAC (one bar= one tumor, max. 2 per mouse). g Schematic of the proposed
processes driving the response to tyrosine kinase inhibition (TKI) and IVT4 treatment (Casp-dep. CD= Caspase-dependent cell death, RTK= receptor
tyrosine kinase). Significance was calculated as FDR-adjusted q-values (a, b), by two-way ANOVA adjusting for the mouse in osi or vehicle groups (c, d),
two-sample t tests (e), and one-sample t tests (f). All tests are two-sided. Source data are provided as a Source Data file.
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Together with the lack of detectable IFN in the medium super-
natant, this suggests a cell-autonomous process. Considering the
time dynamics, the lack of robust IFN secretion by treated cells,
the limited engagement of the TBK1–IRF3 axis, and the sustained
activation following MAVS knock-out indicate a tumor cell-
autonomous process distinct from previously described
mechanisms52. It has also been shown that cell death can modify
and engage inflammatory programs53. However, our in vitro data
using caspase-inhibitors to prevent cell death following kinase
inhibition suggests that this is not likely a major driver of the
observed effects. Our data rather suggest that suppression of
MAPK activity induces a de novo transcription of IRF1 and of
other IRF family members leading to a TBK1/IRF3-independent
inflammatory reprogramming.
Similar drug-induced inflammatory response profiles have
been suggested to enhance ICB efficacy14,16. In general, ICB has
shown relevant benefits across many cancer entities, however in
several oncogene-driven tumors responses have been dis-
appointing, e.g. in ALK- or EGFR-driven lung cancer54,55, where
ICB may even be related with severely increased adverse event
rates in certain scenarios56. In accordance with previous reports,
PD-L1 expression depended upon EGFR activity57 and PD-1/
EGFR inhibitor combination could not prevent tumor outgrowth
in our humanized PDX models. At the same time, we observed an
upregulation of alternative immune checkpoints such as VTCN1
(B7-H4), which has been associated with limited ICB response
and reduced T-cell activity previously41,58. Of note, upregulation
of VTCN1 was not observed in BRAF-mutant melanoma cells or
patient samples, indicating additional levels of regulation.
Among the genes induced during inflammatory reprogram-
ming, we also noticed several members of the innate immune
system including NARs like RIG-I (DDX58). Activation of NARs
in tumor cells by intrinsic and extrinsic agonists has been shown
previously to invoke anti-tumor responses16,24,48,51. Among the
tested NAR agonists, IVT4 activating RIG-I was able to induce an
IFN response across the cell lines and induced TBK1-IRF3 sig-
naling. This inflammatory response was accompanied by the
upregulation of pro-apoptotic genes such as PUMA and NOXA
and resulted in cytotoxicity across different cell lines. More
importantly, in combination with targeted treatment IVT4 was
able to significantly increase cell death in a MAVS-dependent
fashion in vitro. These findings also translated into robust tumor
shrinkage of immune-competent EGFR-driven in vivo models
when IVT4 was combined with the EGFR inhibitor osimertinib.
Furthermore, the delayed in vivo effects of RIG-I activation
involved the presence of NK- and CD8 cells. Moreover, both in
the humanized xenograft model as well as in the syngeneic mice
IVT4 treatment reduced levels of exhausted CD8 cells, which
further supports immune activation as a mechanism leading to
the efficacy of combined kinase inhibition with RIG-I stimulation.
Thus, while the single-agent kinase inhibitor treatment pro-
motes the recruitment of tumor-infiltrating lymphocytes only the
combination with a RIG-I agonist effectively promotes the
clearance of drug-tolerant persisters. Currently, several agonists
of innate immunity sensors including RIG-I are evaluated in
clinical trials59, and novel RIG-I agonists that can be adminis-
tered orally60 or intravenously26 will help to broaden the scope of
clinical translation.
Taken together, we propose that the drug-induced repro-
gramming of innate immunity signaling can be exploited using
RIG-I agonists to maximize the anti-tumor efficacy of targeted
tumor treatment. Together with the observed induction of
alternative immune checkpoints our findings thus not only offer
insights into the adaptation processes following kinase inhibition
but provide promising novel therapeutic avenues for oncogene-
driven cancers.
Methods
Cell culture. Human cancer cell lines were obtained from ATCC and verified
regularly for Mycoplasma infection and by short tandem repeat (STR) profiling at
the Institute for Forensic Medicine of the University Hospital of Cologne. PC9,
HCC827, HCC4006, BT-474, H3122, A375, and H1993 cells were cultured in
RPMI; Colo205, A375, SKBR3, and HEK293T cells were cultured in DMEM. All
media were supplemented with 10% fetal bovine serum and 1% penicillin/strep-
tomycin. All cells were grown at 37 °C in a humidified atmosphere with 5% CO2.
Primary murine PDAC cell lines had been derived previously from tumor pieces of
Ptf1awt/Cre; Kraswt/LSL-G12D; Trp53loxP/loxP mice38 through incubation in DMEM
high-glucose medium (Thermo Fisher Scientific) supplemented with 10% fetal
bovine serum (Thermo Fisher Scientific) until proliferating tumor cells could be
established.
Immunoblot. Cells were washed with PBS and proteins were extracted in RIPA
buffer with protease inhibitors cOmplete Mini Protease Inhibitor Cocktail (Roche)
and phenylmethylsulfonylfluorid (0.1 mM). Protein concentrations were deter-
mined by BCA assay (Pierce). Equal amounts of protein were separated on 4–20%
Tris–glycine sodium dodecyl sulfate–polyacrylamide gel electrophoresis
(SDS–PAGE) gels (Thermo Fisher Scientific, USA) and transferred to PVDF-FL
membranes (Millipore). Upon blocking, membranes were stained with primary
antibodies overnight, washed, and incubated with fluorescently labeled secondary
antibodies. Fluorescence was detected with the Odyssey CLx imaging system (LI-
COR Biosciences, USA).
Cell viability screening. Cells were seeded as triplicates in 96-well plates (Costar)
and serially diluted drug or DMSO was added the next day. For PDAC cell lines
trametinib was pre-printed using the D300e Digital Dispenser (Tecan, Switzer-
land). Viability was determined after 72 h by CellTiter-Glo assay (CTG) (Promega)
in an Infinite 200 Pro microplate reader (Tecan, Switzerland) for humans and a
Tecan Spark 10M multiple readers for PDAC cell lines. Data were averaged across
replicates and dose–response curves were fitted using R or GraphPad Prism to infer
half-maximal growth-inhibitory (GI50) concentrations.
Viability analysis of combined kinase inhibition and IVT4 treatment. Cells
were seeded in 96-well plates and treated with 100 nM trametinib, 300 nM osi-
mertinib, 1 μM vemurafenib, or DMSO the next day. After 48 h of treatment,
IVT4/IVT-GAC were mixed in Opti-MEM (ThermoFisher, USA) with Lipofecta-
mine 2000 (Invitrogen, USA) and added to achieve a final concentration of 1 ng/μL
IVT4. The next day cell viability was assessed using CellTiter-Glo assay (CTG)
(Promega) in an Infinite 2000 Pro microplate reader (Tecan, Switzerland). Values
were normalized to the respective IVT-GAC controls per compound and cell line.
RNA sequencing. Transcriptome sequencing was generated during this study for
patient-derived cell lines and samples and the lung adenocarcinoma mouse models
were performed using total extracted RNA. 3′ UTR mRNA libraries were generated
from total RNA using the Lexogen QuantSeq kit (Lexogen, Austria) according to
the standard protocol and sequenced on Illumina HiSeq4000 or NovaSeq
sequencer (Illumina, USA). RNA extracted from primary murine PDAC cell lines
was processed using TruSeq Stranded mRNA Kit (Illumina, USA) and sequenced
as 2 × 100 bp on a HiSeq 4000 (Illumina, USA). Raw-sequencing data were aligned
to the respective reference genomes and quantified prior to differential expression
analyses. For details see Supplementary Materials and Methods.
Humanized mouse model. PBMCs were isolated from healthy donor buffy coats
(ethics approval 18-198, University of Cologne) by Ficoll-Paque density gradient
(GE Healthcare, USA) centrifugation and used without intermittent freezing. 8–10-
week-old NSG mice (NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ) were injected s.c. with
5 × 106 PC9 cells in both flanks and 10 × 106 healthy donors PBMCs i.p. Tumor
growth was monitored 2×/week and treatment was commenced on day 17 after
tumor inoculation and PBMC engraftment (Animal study approval number 84-
02.04.2017.A236). The tumor size was approximately 150 mm³ on day 17 when
treatment commenced. For treatment details see Supplementary Materials and
methods.
Syngeneic Egfrmut mouse model. Female C57BL/6J mice were purchased from
Charles River Laboratories Japan, Inc. (Yokohama, Japan). All mice were provided
sterilized food and water and were maintained at an air-conditioned temperature of
22 ± 2 °C with constant humidity under a 12/12-h light/dark cycle. Murine Egfr
mutant adenocarcinoma tumors45 were dissociated into single-cell suspensions by
using a Tumor Dissociation Kit, mouse (Miltenyi Biotec, Germany), red blood cells
were removed from the suspensions (Red Blood Cell Lysis Solution; Miltenyi
Biotec), 50–100 × 104 cells were resuspended in 0.1 mL PBS and 0.1 mL of Matrigel
matrix (Corning, New York, USA), and injected subcutaneously into the back (on
both sides) of C57BL/6J mice. Treatment with osimertinib and IVT4/IVT-GAC
was performed as described in the Supplementary Materials and methods.
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Statistical analyses. Statistical analyses were performed as described in the figure
legend for each experiment. Data are expressed as mean ± SEM with significance
set at p < 0.05 unless otherwise noted. The sample size was not predetermined. All
samples meeting proper experimental conditions were included in analyses. Box-
plots: Box edges display 25th and 75th percentile, middle lines the median and
whiskers extend to the value max. 1.5*IQR of the box edges (IQR= interquartile
range). Points beyond 1.5*IQR are drawn individually. Statistical significance was
determined as indicated in the figure legends using two-tailed tests using Prism
software (v9.1, GraphPad Software, USA) or the statistical environment R (v3.5.0).
Primers used for RT-qPCR, CRISPR experiments, ChIP analyses, and DNA
sequencing can be found in Supplementary Table S2, gating strategies in
Supplementary Fig. S10. All experiments including animal studies were performed
in agreement with local regulations by trained researchers. Animal experiments
were approved by the Institutional Animal Welfare Committees of the University
of Cologne (84-02.04.2017.A236) and the University of Okayama (OKU-2017412).
Experiments with human material approved by Crown Bioscience and the
University of Cologne (ethics approval 18-198). For additional details please see
Supplementary Materials and methods.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
The RNA-seq data of murine PDAC cells generated in this study have been deposited in
the Gene Expression Omnibus database under accession code GSE181599
(www.ncbi.nlm.nih.gov/geo/). All other sequencing data has been deposited in the
ArrayExpress database under accession codes E-MTAB-9468, E-MTAB-9883, E-MTAB-
9884, E-MTAB-9885, E-MTAB-9887, E-MTAB-9888, E-MTAB-9889, E-MTAB9890, E-
MTAB9891, E-MTAB-9886, E-MTAB-10851 and E-MTAB10802. We also used the
publicly accessible data sets GSE76360 (breast cancer RNA expression), GSE100336
(KRAS G12C expression data) (www.ncbi.nlm.nih.gov/geo/) and EGAS00001000992
(melanoma patient RNA-seq), EGAS00001002335 (LC2/AD RNA-seq) (https://ega-
archive.org). The remaining data are available within the Article, Supplementary
Information or Source Data file. Source data are provided with this paper.
Materials availability
Further information and requests for resources and reagents should be directed to and
will be fulfilled upon reasonable request by the Lead Contact, Martin Sos. Source data are
provided with this paper.
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